A
Angela L. Davis
Researcher at University of Arizona
Publications - 6
Citations - 1545
Angela L. Davis is an academic researcher from University of Arizona. The author has contributed to research in topics: HSPA1A & Heat shock. The author has an hindex of 5, co-authored 6 publications receiving 1448 citations.
Papers
More filters
Journal ArticleDOI
Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.
Breland Smith,Hui-Hua Chang,Federico Medda,Vijay Gokhale,Justin Dietrich,Angela L. Davis,Emmanuelle J. Meuillet,Christopher Hulme +7 more
TL;DR: This Letter presents the synthesis and biological evaluation of a collection of 2-aminothiazoles as a novel class of compounds with the capability to reduce the production of PGE(2) in HCA-7 human adenocarcinoma cells exhibiting promising anti-cancer activity.
Journal ArticleDOI
The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells
Angela L. Davis,Shuxi Qiao,Jessica L. Lesson,Montserrat Rojo de la Vega,Sophia L. Park,Carol Seanez,Vijay Gokhale,Christopher M. Cabello,Georg T. Wondrak +8 more
TL;DR: The data suggest feasibility of apoptotic elimination of malignant melanoma cells using the quinone methide-derived heat shock response inducer aurin and suggest cancer cell proteostasis can be undermined using aurin as a proteotoxic experimental therapeutic.
Journal ArticleDOI
Phenotypic Identification of the Redox Dye Methylene Blue as an Antagonist of Heat Shock Response Gene Expression in Metastatic Melanoma Cells
TL;DR: Feelings are suggested of feasibility of repurposing the non-oncological redox drug MB as a therapeutic heat shock response antagonist for cancer cell chemosensitization.
Journal ArticleDOI
DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma.
Christopher M. Cabello,Sarah D. Lamore,Warner B. Bair,Angela L. Davis,Sara Azimian,Georg T. Wondrak +5 more
TL;DR: In a murine xenograft model of human homozygous NQO1*2-breast carcinoma, systemic administration of DCPIP displayed significant anti-tumour activity, suggesting feasibility of redox chemotherapeutic intervention targeting the NQM*2 genotype.